Chan Leakhena Phoeung

Chan Leakhena Phoeung

Auto-generated profile, based on publicly available information

Chan Leakhena Phoeung

University of Health Sciences, Phnom Penh, Cambodia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
MIMalin Inghammar
Malin Inghammar
YBYoulet By
Youlet By
CFChristina Farris
Christina Farris
TPThong Phe
Thong Phe
LBLaurence Borand
Laurence Borand
ATArnaud Tarantola
Arnaud Tarantola
Childhood vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in Cambodia in January 2015. Baseline data regarding circulating serotypes are scarce. All microbiology laboratories in Cambodia were contacted for identification of stored isolates of Streptococcus pneumoniae from clinical specimens taken before the introduction of PCV13. Available isolates were serotyped using a multiplex polymerase chain reaction method. Among 166 identified isolates available for serotyping from patients with pneumococcal disease, 4% were isolated from upper respiratory samples and 80% were from lower respiratory samples, and 16% were invasive isolates. PCV13 serotypes accounted for 60% (95% confidence interval [CI] 52–67) of all isolates; 56% (95% CI 48–64) of noninvasive and 77% (95% CI 57–89) of invasive isolates. Antibiotic resistance was more common among PCV13 serotypes. This study of clinical S. pneumoniae isolates supports the potential for high reduction in pneumococcal disease burden and may serve as baseline data for future monitoring of S. pneumoniae serotypes circulation after implementation of PCV13 childhood vaccination in Cambodia.

9 October 2025 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
DKDyna Khuon
Dyna Khuon
LSLuis Sagaon-Teyssier
Luis Sagaon-Teyssier
SNSansothy Neth
Sansothy Neth
SSSaly Saint
Saly Saint
LMLaurence Meyer
Laurence Meyer
VSVonthanak Saphonn
Vonthanak Saphonn
The estimated prevalence of hepatitis C virus (HCV) infection among adults aged over 45 years in Cambodia is approximately 5%. The present study aimed assessing the effectiveness of a novel community-based strategy comprising HCV rapid testing (RDT) and dried blood spot (DBS) collection performed by community health workers (CHWs) in outreach contexts. ANRS 12384 Cam-C is a parallel arm cluster randomized controlled trial conducted in the Siem Reap and Kampong Cham provinces of Cambodia between April 2022 and September 2023. Four geographical areas in each province were randomized into two arms to compare HCV RDT and DBS collection provided in homes by community health workers (i.e., community-based strategy) with facility-based HCV RDT and whole blood collection provided by healthcare workers in health centers (i.e., facility-based strategy). The primary outcome was combined testing uptake, defined as the proportion of participants who were actually tested for HCV using RDT or RDT/RNA if positive out of all those who participated in the study. Mixed effects logistic models were used to estimate the effect of the community-based strategy. The study is registered on ClinicalTrials.gov (NCT03992313). Among the 7692 participants who initially enrolled in the study, 5590 (72.7%) actually went on to have HCV RDT or HCV RDT/RNA screening (i.e., combined testing uptake). Combined testing uptake in the community-based (2990 participants) and facility-based (2600 participants) arms was 78.1% and 67.3%, respectively (p < 0.001). Positive HCV RDT was found for 57 (2.2%) including 39 (1.5%) with detectable HCV RNA among participants in the facility-based arm. In the community-based arm, 37 (1.2%) had positive HCV RDT including 32 (1.1%) with detectable HCV RNA. Treatment uptake concerned 36 participants (out of 39 with positive HCV RDT) and 30 (out of 32) in the facility-based and community-based arms, respectively. The odds of combined testing uptake in the community-based strategy were 2.18 (95% CI [1.28–3.73], p = 0.004) times higher than in the facility-based strategy. Combined testing uptake (HCV RDT or HCV RDT/RNA) was higher for the community-based strategy than for the facility-based strategy. The involvement of community health workers improved first contact with HCV services and uptake. Integrating this trial's community-based screening strategy into the national Cambodian HCV program could improve its effectiveness as part of the country's broader goal of eliminating HCV by 2030. This study was supported by the 10.13039/501100003323 ANRS MIE (ANRS 12384).

20 November 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
EMEmilie Mosnier
Emilie Mosnier
OSOlivier Segeral
Olivier Segeral
SNSansothy Neth
Sansothy Neth
LSLuis Sagaon-Teyssier
Luis Sagaon-Teyssier
DKDyna Khuon
Dyna Khuon
VSVonthanak Saphonn
Vonthanak Saphonn
Background: In Cambodia, hepatitis C constitutes a significant public health challenge, particularly among older adults (>45 years) for whom prevalence is estimated to be 5%. To facilitate the elimination of hepatitis C among the general population, enhancing access to screening and treatment is imperative. In this regard, the evaluation of community-based screening programs emerges as a crucial step toward improving health care accessibility. Objective: This study aims to assess the comparative efficacy of a community-based versus a facility-based approach in enhancing the uptake of hepatitis C antibody testing among the general population older than 40 years of age in Cambodia. Methods: The CAM-C (Community Versus Facility-Based Services to Improve the Screening of Active Hepatitis C Virus Infection in Cambodia) study uses a cluster-randomized controlled trial design across two Cambodian provinces to compare community-based and facility-based hepatitis testing interventions. Sampling involves a multistage cluster approach, targeting individuals older than 40 years of age due to their higher prevalence and risk of chronic hepatitis complications. This study incorporates a qualitative analysis of acceptability and a cost-effectiveness comparison. Interventions include facility-based testing with subsequent referral and community-based testing with direct in-home assessments. Follow-up for positive cases involves comprehensive management and potential direct-acting antiviral treatment. This study aims to identify a significant increase in testing uptake, requiring the screening of 6000 individuals older than 40 years of age, facilitated by a structured sampling and intervention approach to minimize contamination risks. Results: The final protocol including the quantitative, qualitative, and cost-effectiveness part of the study was registered and was approved in 2019 by the National Ethical Cambodian for Health Research. Inclusions were completed by mid-2024, with analyses starting in May 2024. Conclusions: Using a mixed methods approach that combines a robust methodology (cluster-randomized controlled trial) with a cost-effectiveness analysis and qualitative research, such a study should provide invaluable information to guide the Ministry of Health in its hepatitis C virus screening strategy and move toward elimination. Trial Registration: ClinicalTrials.gov NCT03992313; https://clinicaltrials.gov/study/NCT03992313 International Registered Report Identifier (IRRID): DERR1-10.2196/63376

9 September 2025 in Vaccine
Verified
Journal Article
Closed access
PLPhoeung Chan Leakhena
Phoeung Chan Leakhena
SAShally Awasthi
Shally Awasthi
MRMuriel Rabilloud
Muriel Rabilloud
RDRachel Daw
Rachel Daw
NVNeha Verma
Neha Verma
VPValentina Sanchez Picot
Valentina Sanchez Picot

16 May 2025 in BMJ Global Health
Verified
Journal Article
Open access
CCCécile Chauvel
Cécile Chauvel
PVPhilippe Vanhems
Philippe Vanhems
MQMarie-Charlotte Quemin
Marie-Charlotte Quemin
MAMarianne Abifadel
Marianne Abifadel
SAShally Awasthi
Shally Awasthi
FPFlorence Komurian Pradel
Florence Komurian Pradel
Introduction: The Global Approach to Biology Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) network is an international scientific network of 21 centres coordinated by the Merieux Foundation (Lyon, France). Mapping and characterising the similarities and differences in expertise and activities across four major infectious diseases (tuberculosis, antimicrobial-resistant infections, acute respiratory infections and emerging pathogens) among these centres would help to provide a better understanding of the network’s capacity. It will also highlight how the applied methodology can enhance information sharing within research networks. Methods: Each centre responded to a questionnaire on their core activities and research themes. An advanced multivariate analysis was performed to relate all items together and highlight new synergies among members of the GABRIEL network. Similarities were found using a clustering algorithm and data were visualised using alluvial plots. Results: This strategy enabled to find new patterns in the GABRIEL network for the implementation of new projects on global health, regardless of geographical proximity or historical connections. Five clusters based on core activities, consisting of 6, 1, 3, 9 and 2 research units, respectively, have been identified, with clusters 1 and 4, including the majority of the units. Four clusters have been defined based on the four major infectious diseases, comprising 7, 3, 5 and 6 research units, respectively. Conclusions: The same methodology could also be applied to identify proximities on other networks of experts or between members of different networks for more efficient research or surveillance global programmes.

6 January 2025 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
CPChan Leakhena Phoeung
Chan Leakhena Phoeung
JPJacqueline Prestedge
Jacqueline Prestedge
MNMarilyn Ninan
Marilyn Ninan
PCPhilip Cunningham
Philip Cunningham
SBSothavireak Bory
Sothavireak Bory
VSVonthanak Saphonn
Vonthanak Saphonn
Rapid antigen diagnostic tests (Ag-RDTs) that quickly and accurately identify SARS-CoV-2 are an essential part of the COVID-19 response, but multiple factors can affect the validity of Ag-RDTs results. In Cambodia, several commercial Ag-RDTs have become available since the COVID-19 outbreak, but quality control (QC) and external quality assurance (EQA) of these rapid tests have yet to be fully and systematically implemented. We collaborated with laboratory experts in Australia and piloted an EQA programme of the commonly used COVID-19 Ag-RDTs at the University of Health Sciences’ MERIEUX Laboratory (Tier 1 site—responsible for the in-country receipt and distribution of QA material) and four other participating laboratories (Tier 2—healthcare facility based) between November 2021 and November 2022. The preimplementation training including the Khmer-translated documentation was conducted virtually for Tier 1 laboratories and in-person for Tier 2 laboratories. All QC (n=290) and EQA (n=60) specimens were distributed to the laboratories and testing was performed according to the frequency of Ag-RDTs use in each laboratory. All National Reference Laboratory-provided EQA and QC specimens were tested and results were submitted via the EDCNet portal using QR code scanning. The Tier 1 laboratory reported 100% concordance with the EQA reference result, while some of Tier 2 laboratories’ results were discordant. While continued capacity building and support with troubleshooting have been key to the successful EQA piloting at the UHS laboratory, the programme experienced delays in the shipping/delivery of EQA and QC panels due to customs and border requirements, which could have hindered implementation and potentially impacted the quality of the QA materials. The pilot EQA programme demonstrated potential scalability and provided data on the reliability of test results at the site. However, to ensure sustainability and practicability of this activity, in-country EQA panel preparation may need to be considered.